AD AMPK Activator and Energy Metabolism Companies

📖 Wiki Page

company1699 wordssynced 2026-04-02

Overview

flowchart TD companies_ad_ampk_activator_en["AD AMPK Activator and Energy Metabolism Companie"] style companies_ad_ampk_activator_en fill:#4fc3f7,stroke:#333,color:#000 companies_ad_ampk_ac_0["Scientific Rationale"] companies_ad_ampk_activator_en -->|"includes"| companies_ad_ampk_ac_0 style companies_ad_ampk_ac_0 fill:#81c784,stroke:#333,color:#000 companies_ad_ampk_ac_1["Relationship to Other Categories"] companies_ad_ampk_activator_en -->|"includes"| companies_ad_ampk_ac_1 style companies_ad_ampk_ac_1 fill:#ef5350,stroke:#333,color:#000 companies_ad_ampk_ac_2["Direct AMPK Activators Research Stage"] companies_ad_ampk_activator_en -->|"includes"| companies_ad_ampk_ac_2 style companies_ad_ampk_ac_2 fill:#ffd54f,stroke:#333,color:#000 companies_ad_ampk_ac_3["Novel CNS-Optimized AMPK Agonists"] companies_ad_ampk_activator_en -->|"includes"| companies_ad_ampk_ac_3 style companies_ad_ampk_ac_3 fill:#ce93d8,stroke:#333,color:#000 companies_ad_ampk_ac_4["Indirect AMPK Activators Non-GLP-1"] companies_ad_ampk_activator_en -->|"includes"| companies_ad_ampk_ac_4 style companies_ad_ampk_ac_4 fill:#4fc3f7,stroke:#333,color:#000 companies_ad_ampk_ac_5["Berberine and Natural Compounds"] companies_ad_ampk_activator_en -->|"includes"| companies_ad_ampk_ac_5 style companies_ad_ampk_ac_5 fill:#81c784,stroke:#333,color:#000

...

Overview

Mermaid diagram (expand to render)

This category page catalogs biotechnology and pharmaceutical companies developing AMPK (AMP-activated protein kinase) activator therapies and broader energy metabolism modulators for Alzheimer's disease (AD). These approaches target the fundamental bioenergetic deficits, impaired autophagy, and mitochondrial dysfunction that are hallmarks of AD pathophysiology.

<div class="infobox">
<div class="infobox-header">AMPK and Energy Metabolism Pipeline Overview</div>
<div class="infobox-content">
<table>
<tr><th>Category</th><th>Companies</th></tr>
<tr><td>Direct AMPK Activators</td><td>Research stage</td></tr>
<tr><td>Indirect AMPK Activators (non-GLP-1)</td><td>4</td></tr>
<tr><td>Mitochondrial Function Modulators</td><td>3</td></tr>
<tr><td>Autophagy Enhancers</td><td>2</td></tr>
<tr><td>Metabolic/Bioenergetic</td><td>4</td></tr>
<tr><td>Phase 2 Trials</td><td>2</td></tr>
<tr><td>Phase 1 Trials</td><td>2</td></tr>
<tr><td>Preclinical/Discovery</td><td>5+</td></tr>
</table>
</div>
</div>

Scientific Rationale

AMPK is a central cellular energy sensor that coordinates metabolic homeostasis. In Alzheimer's disease, AMPK dysregulation contributes to:

Impaired autophagy: Failure to clear [amyloid-beta](/proteins/amyloid-beta) and [tau](/proteins/tau) aggregates
Mitochondrial dysfunction: Reduced ATP production in energy-hungry neurons
Neuroinflammation: AMPK regulates microglial inflammatory responses
Synaptic failure: Energy deficits impair synaptic plasticity and function
Insulin resistance: Linked to type 2 diabetes and AD risk[@marinangeli2020][@yang2020]

Activated AMPK phosphorylates key therapeutic targets: mTOR (autophagy), ULK1 (autophagy initiation), PGC-1α (mitochondrial biogenesis), and TFEB (lysosomal biogenesis)[@hardie2023]. This cascade offers multiple mechanisms for disease modification beyond amyloid and tau targeting.

Relationship to Other Categories

This page covers AMPK activators and energy metabolism approaches beyond GLP-1/SGLT2/metformin, which are catalogued in the [AD Metabolic and GLP-1 Based Therapy Companies](/companies/ad-glp-1-metabolic-therapy-companies) page. The focus here is on:

Direct AMPK activators (research stage)
Novel indirect AMPK activators (non-GLP-1 mechanisms)
Mitochondrial-targeted therapies with AD programs
Autophagy enhancers with AD programs
Brain metabolic modulators beyond PPAR/GLP-1

Direct AMPK Activators (Research Stage)

Novel CNS-Optimized AMPK Agonists

While no direct AMPK activator has reached clinical trials for AD, several compound classes are in preclinical development:

| Compound | Type | Notes |
|----------|------|-------|
| Compound 991 | Direct allosteric activator | β1-selective, high potency |
| A-769662 | Direct β1 activator | Demonstrated in neurodegeneration models |
| PT1 | Allosteric AMPK activator | Brain-penetrant derivatives in development |
| Thienopyridone derivatives | Direct AMPK activators | CNS-optimized prodrugs |
| MK-8722 | Pan-AMPK activator | Excellent glucose homeostasis; cardiac hypertrophy concern[@myers2017] |

Key Challenge: Brain penetration remains the primary hurdle. Current research focuses on:

Prodrug approaches (improved BBB penetration)
β1-isoform selectivity (reduce peripheral effects)
Novel delivery systems (nanoparticles, intranasal)

Academic Programs: Multiple university labs are developing brain-penetrant AMPK activators, including programs at MIT, UC San Diego, and University of Pennsylvania.

Indirect AMPK Activators (Non-GLP-1)

Berberine and Natural Compounds

Partex Pharma / Academic Programs

Focus: Berberine and botanical AMPK activators
Mechanism: Indirect AMPK activation via gut microbiome modulation and mitochondrial complex I inhibition
Status: Research/Phase 1
Notes: Better CNS penetration than metformin; multi-target effects; GI side effects limit dosing

Am最rr Natural Health

Focus: Resveratrol and polyphenol AMPK activators
Mechanism: SIRT1-mediated AMPK activation
Status: Research
Notes: Limited by poor bioavailability; nano-formulations in development

Mitochondrial Function Modulators

Vandria SA

Ticker: Private
Headquarters: Geneva, Switzerland
Focus: Mitochondrial quality control and cellular energetics
Lead Candidate: VNA-318
Indication: Alzheimer's disease, Parkinson's disease
Stage: Phase 1
Mechanism: Small molecule targeting mitochondrial dynamics, promoting mitophagy and neuronal survival
Notes: Swiss biotech with expertise in mitochondrial biology; dual AD/PD programs; targets the PINK1/Parkin pathway for clearance of damaged mitochondria
Page: [Vandria SA](/companies/vandria)
Related: [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction-ad), [Mitochondrial Quality Control](/mechanisms/ampk-mitochondrial-quality-control)

Cyteir Therapeutics

Ticker: Private
Headquarters: Lexington, Massachusetts, USA
Focus: Mitochondrial dynamics and DNA repair
Mechanism: Targeting mitochondrial DNA repair mechanisms and dynamics (fusion/fission balance)
Indication: Alzheimer's disease (exploratory)
Stage: Discovery/Preclinical
Notes: Emerging program in neurodegeneration; core platform in cancer could translate to AD
Related: [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction-ad)

Clene Nanomedicine

Ticker: NASDAQ: CLNN
Headquarters: Salt Lake City, Utah, USA
Focus: Nanotherapeutic approach to cellular energy impairment
Lead Candidate: CNM-Au8 (gold nanocrystals)
Indication: ALS (primary), Parkinson's disease (primary), Alzheimer's disease (exploratory)
Stage: Phase 2 (PD, ALS); Phase 1 (AD exploratory)
Mechanism: Gold nanocrystals catalyze redox reactions, supporting mitochondrial function, reducing oxidative stress, and enhancing neuronal survival
Notes: CNM-Au8 (formerly CNM-201) has shown efficacy in animal models of PD and ALS; ACTIVE clinical trial in PD; exploratory AD program underway; indirect AMPK activation through improved bioenergetics
Page: [Clene Nanomedicine](/companies/clene)
Related: [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction-ad), [Oxidative Stress](/mechanisms/oxidative-stress-neurodegeneration)

Autophagy Enhancers

Retro Biosciences

Ticker: Private
Headquarters: San Francisco, California, USA
Focus: Autophagy and cellular clearance
Lead Candidate: RB-001
Indication: Alzheimer's disease
Stage: Phase 1
Mechanism: Autophagy enhancement to clear protein aggregates (amyloid-beta, tau); also developing senolytic approaches
Notes: Founded by Sam Altman and others; significant funding; addresses fundamental protein clearance deficit in AD; Phase 1 safety data expected 2025
Page: [Retro Biosciences](/companies/retro-biosciences)
Related: [Autophagy-Lysosomal Pathway](/mechanisms/autophagy-lysosomal-pathway), [AMPK Signaling Pathway](/mechanisms/ampk-signaling-pathway)

Autophagy Therapeutics Inc.

Ticker: Private
Focus: Small molecule autophagy enhancers
Mechanism: ULK1 activation, mTOR-independent autophagy pathways
Indication: Alzheimer's disease, Parkinson's disease
Stage: Discovery/Preclinical
Notes: Academic spin-out; novel mechanism targeting TFEB nuclear translocation
Related: [Autophagy-Lysosomal Pathway](/mechanisms/autophagy-lysosomal-pathway)

Metabolic and Bioenergetic Approaches

T3D Therapeutics

Ticker: Private
Headquarters: Research Triangle Park, North Carolina, USA
Focus: Metabolic dysfunction in AD
Lead Candidate: T3D-959 (PPAR δ/γ dual agonist)
Indication: Alzheimer's disease
Stage: Phase 2 (PIONEER trial)
Mechanism: Improves brain glucose uptake, mitochondrial function, reduces neuroinflammation; secondary AMPK activation through improved insulin sensitivity
Notes: FDA Fast Track designation; first-in-class metabolic therapy for AD; primary endpoint in PIONEER trial
Page: [T3D Therapeutics](/companies/t3d-therapeutics)
Related: [Brain Metabolic Dysfunction](/mechanisms/brain-metabolic-dysfunction), [PPAR Signaling](/mechanisms/ppar-signaling-pathway)

Athira Pharma

Ticker: NASDAQ: ATHA
Headquarters: Bothell, Washington, USA
Focus: Neurotrophic factor enhancement and metabolic support
Lead Candidate: Fosramutstat (ATH-102)
Indication: Alzheimer's disease
Stage: Phase 1
Mechanism: Small molecule that increases HGF/c-Met signaling, enhancing neurogenesis, synaptic function, and neuronal metabolism; improves mitochondrial function
Notes: HGF (hepatocyte growth factor) system supports neuronal repair and metabolic function; positive Phase 1 interim data; Phase 2 planned
Page: [Athira Pharma](/companies/athira-pharma)
Related: [Neurotrophic Factor Signaling](/mechanisms/neurotrophic-factor-pathway), [Neurogenesis](/mechanisms/neurogenesis-ad)

Cerecin

Ticker: Private
Headquarters: Singapore
Focus: Cerebral blood flow and metabolic enhancement
Lead Candidate: CPP-115 (GABA transaminase inhibitor)
Indication: Alzheimer's disease
Stage: Preclinical
Mechanism: GABA transaminase inhibition improves energy metabolism in neurons; targets vascular function alongside metabolism
Notes: Singapore-based company with strong metabolic focus; explores intersection of vascular dysfunction and energy metabolism in AD
Related: [Neurovascular Coupling](/mechanisms/neurovascular-coupling-ad), [Cerebral Blood Flow](/mechanisms/cerebral-blood-flow-ad)

Biohaven Pharmaceutical Holding Company Ltd.

Ticker: NYSE: BHVN (acquired by Pfizer)
Headquarters: New Haven, Connecticut, USA
Focus: Metal binding, metabolic approaches, TRPM2 modulators
Lead Candidates: Troriluzole (BHV-4157), BHV-7000 (TRPM2 modulator)
Indication: Alzheimer's disease
Stage: Phase 2 (Troriluzole); Preclinical (TRPM2)
Mechanism: Troriluzole: sigma-1 agonist with metal chelation properties and metabolic support; TRPM2: calcium channel modulation supporting neuronal metabolism
Notes: Pfizer acquisition expands resources; sigma-1 receptor localization to mitochondria-associated membranes links to metabolic effects; Phase 2 data anticipated 2025
Page: [Biohaven](/companies/biohaven)
Related: [Metal Homeostasis](/mechanisms/metal-homeostasis-neurodegeneration), [Sigma-1 Receptor](/mechanisms/sigma-1-receptor-neurodegeneration)

Emerging and Early-Stage Programs

Calico (Alphabet)

Ticker: Private (Alphabet subsidiary)
Focus: Longevity and metabolic interventions
Notes: Exploring AMPK-activating approaches; significant resources; academic-style research model
Related: [Calico](/companies/calico)

Cohere Health / Academic Spinoffs

Multiple academic programs are developing AMPK-targeting and energy metabolism approaches for AD:

| Institution | Approach | Status |
|-------------|----------|--------|
| UC San Diego | Novel brain-penetrant AMPK activators | Preclinical |
| University of Michigan | Mitochondrial-targeted peptides | Research |
| Columbia University | TFEB activators for autophagy | Research |
| Scripps Research | Natural product AMPK modulators | Research |

Pipeline Overview

| Company | Drug/Candidate | Mechanism | Phase | Indication |
|---------|---------------|-----------|-------|-------------|
| T3D Therapeutics | T3D-959 | PPAR δ/γ agonist (metabolic) | Phase 2 | AD |
| Retro Biosciences | RB-001 | Autophagy enhancement | Phase 1 | AD |
| Vandria SA | VNA-318 | Mitochondrial modulator | Phase 1 | AD/PD |
| Clene Nanomedicine | CNM-Au8 | Nanocatalytic bioenergetic | Phase 2 | PD/ALS; AD exploratory |
| Athira Pharma | Fosramutstat (ATH-102) | HGF/c-Met agonist (metabolic) | Phase 1 | AD |
| Biohaven | Troriluzole (BHV-4157) | Sigma-1/metal chelation | Phase 2 | AD |
| Biohaven | BHV-7000 | TRPM2 calcium channel | Preclinical | AD |
| Cerecin | CPP-115 | GABA transaminase inhibitor | Preclinical | AD |
| Various | Direct AMPK agonists | Direct AMPK activation | Research | AD/PD |

Key Challenges and Opportunities

Challenges

Blood-brain barrier penetration: Many AMPK activators have poor CNS exposure

Isoform selectivity: Non-selective AMPK activation causes peripheral adverse effects

Dose optimization: Chronic vs. acute activation may require different approaches

Biomarkers: Need pharmacodynamic markers for AMPK activation in brain tissue

Mechanism complexity: AMPK has both protective and pathological roles depending on context

Opportunities

Exercise mimetics: Novel compounds that recapitulate AMPK-dependent exercise benefits

Combination approaches: AMPK activation + autophagy enhancement + mitochondrial support

Stage-specific targeting: Pre-symptomatic (preventive) vs. symptomatic (therapeutic)

Biomarker development: p-AMPK, PGC-1α, LC3 as pharmacodynamic endpoints

Repurposing: Existing metabolic drugs with AMPK activity (berberine, salicylates)

Cross-References

[AMPK Signaling Pathway](/mechanisms/ampk-signaling-pathway)
[AMPK Signaling in Neurodegeneration](/mechanisms/ampk-neurodegeneration)
[AMPK Signaling in Alzheimer's Disease](/mechanisms/ampk-neurodegeneration)
[Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction-ad)
[Autophagy-Lysosomal Pathway](/mechanisms/autophagy-lysosomal-pathway)
[Brain Metabolic Dysfunction](/mechanisms/brain-metabolic-dysfunction)
[Mitochondrial Quality Control](/mechanisms/ampk-mitochondrial-quality-control)

[AD Metabolic and GLP-1 Based Therapy Companies](/companies/ad-glp-1-metabolic-therapy-companies)
[AD Mitochondria-Targeting Companies](/companies/ad-mitochondria-targeting-companies)
[PD AMPK Activator Companies](/companies/pd-ampk-activator-companies)
[PD Metabolic Intersection Companies](/companies/pd-metabolic-intersection-companies)

[AMPK Activators for Neurodegeneration](/therapeutics/ampk-activators-neurodegeneration)
[AMPK Activators in Parkinson's Disease](/mechanisms/ampk-activators-parkinsons)
[Metformin for Neurodegeneration](/therapeutics/metformin-neurodegeneration)
[Autophagy Modulation](/mechanisms/autophagy-lysosomal-pathway)

[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)

References

[Marinangeli C, et al, AMPK as a therapeutic target for neurodegenerative diseases, Current Neuropharmacology (2020)](https://pubmed.ncbi.nlm.nih.gov/32106820/)

[Hardie DG, AMPK: positive and negative regulation by upstream kinases, Int J Mol Sci (2023)](https://pubmed.ncbi.nlm.nih.gov/37047345/)

[Yang L, et al, AMPK: Potential Therapeutic Target for Alzheimer's Disease, Curr Protein Pept Sci (2020)](https://pubmed.ncbi.nlm.nih.gov/31424367/)

[Curry DW, et al, Targeting AMPK Signaling as a Neuroprotective Strategy in Parkinson's Disease, J Parkinson's Disease (2018)](https://doi.org/10.3233/JPD-171296)

[Myers RW, et al, Systematic pan-AMPK activator MK-8722 improves glucose homeostasis but induces cardiac hypertrophy, Science (2017)](https://doi.org/10.1126/science.aan3600)

📖 View canonical wiki page →

AD AMPK Activator and Energy Metabolism Companies

Overview

Overview

Scientific Rationale

Relationship to Other Categories

Direct AMPK Activators (Research Stage)

Novel CNS-Optimized AMPK Agonists

Indirect AMPK Activators (Non-GLP-1)

Berberine and Natural Compounds

Partex Pharma / Academic Programs

Am最rr Natural Health

Mitochondrial Function Modulators

Vandria SA

Cyteir Therapeutics

Clene Nanomedicine

Autophagy Enhancers

Retro Biosciences

Autophagy Therapeutics Inc.

Metabolic and Bioenergetic Approaches

T3D Therapeutics

Athira Pharma

Cerecin

Biohaven Pharmaceutical Holding Company Ltd.

Emerging and Early-Stage Programs

Calico (Alphabet)

Cohere Health / Academic Spinoffs

Pipeline Overview

Key Challenges and Opportunities

Challenges

Opportunities

Cross-References

Related Mechanism Pages

Related Company Pages

Related Therapeutic Pages

Related Disease Pages

References